This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SPARCL | |
|---|---|
| Name | SPARCL |
| Acronym | SPARCL |
| Phase | III |
| Design | Randomized, double-blind, placebo-controlled |
| Started | 1998 |
| Completed | 2006 |
| Primary investigator | Lawrence H. Leiter |
| Sponsor | AstraZeneca |
| Patients | ~4,731 |
| Condition | Stroke prevention after transient ischemic attack or stroke |
| Intervention | High-dose atorvastatin (80 mg) vs placebo |
SPARCL The Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial was a landmark randomized, double-blind, placebo-controlled study evaluating high-dose atorvastatin for secondary prevention after cerebrovascular events. The trial influenced clinical practice guidelines and intersected with major trials and organizations shaping cardiovascular and cerebrovascular care.
The conception of the trial followed evolving evidence from landmark trials such as 1994 Scandinavian Simvastatin Survival Study and Heart Protection Study, and developments within AstraZeneca and academic centers including Columbia University, McMaster University, and McGill University. Investigators responded to findings from the Cholesterol Treatment Trialists' Collaboration and regulatory discussions at the Food and Drug Administration and European Medicines Agency. The protocol drew on preceding work in lipidology by groups linked to National Institutes of Health, American Heart Association, American Stroke Association, and investigators associated with New England Journal of Medicine and Lancet publications.
Primary objectives mirrored hypotheses discussed at meetings such as the World Stroke Congress and reviews in Journal of the American College of Cardiology: that intensive lowering of low-density lipoprotein cholesterol with high-dose atorvastatin would reduce recurrent stroke and major cardiovascular events compared with placebo. Secondary objectives referenced outcomes emphasized by Centers for Disease Control and Prevention, European Society of Cardiology, and consensus statements from panels including members of Oxford University and Harvard Medical School.
SPARCL used a multi-center, randomized, double-blind, placebo-controlled design implemented across sites affiliated with institutions like Johns Hopkins Hospital, Massachusetts General Hospital, Toronto General Hospital, and international centers in United Kingdom, France, Germany, and Japan. The statistical plan adopted methods established by investigators from Stanford University and University of Oxford and aligned with reporting standards promoted by CONSORT initiatives and editors at New England Journal of Medicine.
Participants were adults with recent transient ischemic attack or stroke, many recruited from stroke units associated with Mount Sinai Hospital (New York), Royal London Hospital, and Karolinska University Hospital. Inclusion criteria specified recent noncardioembolic ischemic cerebrovascular events, aligning with diagnostic criteria used by panels at World Health Organization conferences and echoing enrollment practices seen in trials conducted at Mayo Clinic and Cleveland Clinic.
The active intervention was atorvastatin 80 mg daily; the comparator was matched placebo. Concomitant secondary prevention treatments reflected guidelines from American Heart Association, European Stroke Organisation, and practices at centers such as UCLA Health and Vanderbilt University Medical Center, including antiplatelet therapy (aspirin), antihypertensive regimens informed by studies like ALLHAT, and glucose management informed by recommendations from American Diabetes Association.
Primary outcome reduction included fewer recurrent strokes and composite major cardiovascular events, reported in high-impact venues including New England Journal of Medicine and summarized in reviews by Cochrane Collaboration. Results influenced guideline updates from American Heart Association and European Society of Cardiology and were cited in meta-analyses by the Cholesterol Treatment Trialists' Collaboration and systematic reviews incorporating data from trials such as PROVE-IT TIMI 22 and TNT.
Safety signals included an observed increase in hemorrhagic stroke risk, which prompted debate among investigators and commentators from institutions like Beth Israel Deaconess Medical Center, Johns Hopkins University, and editorialists at The Lancet. Regulatory bodies including the Food and Drug Administration and European Medicines Agency considered the risk–benefit profile alongside safety data from pharmacovigilance databases maintained by organizations such as World Health Organization and industry surveillance at AstraZeneca.
SPARCL affected clinical practice guidelines from American Heart Association and European Stroke Organisation and informed subsequent trials in lipid management such as IMPROVE-IT and trials of PCSK9 inhibitors at Regeneron Pharmaceuticals and Amgen. Its data have been incorporated into risk models used in guideline panels at National Institutes of Health and educational materials from societies including American College of Cardiology and World Stroke Organization, shaping approaches to secondary prevention in stroke centers from Massachusetts General Hospital to Royal Melbourne Hospital.
Category:Clinical trials